Skip to content

A Possible Therapeutic Role for Adenosine During Inflammation

A Possible Therapeutic Role for Adenosine During Inflammation

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00513110
Enrollment
33
Registered
2007-08-08
Start date
2007-08-31
Completion date
2008-08-31
Last updated
2009-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endotoxemia

Keywords

Endotoxin, Adenosine, Caffeine, AMPD1 polymorphism

Brief summary

The adenosine receptor is known for its anti-inflammatory actions and could therefore be a potential target in the treatment of sepsis and septic shock. Stimulation of the adenosine receptor could potentially lead to a decrease in inflammation and tissue damage. Under normal conditions adenosine is formed either by an intracellular 5'nucleotidase, which dephosphorylates AMP, or by the hydrolysis of S-adenosylhomcysteine by hydrolase. An alternative pathway of AMP degradations is provided by the cytosolic enzyme AMP deaminase (AMPD), which catalyses the irreversible deamination of AMP to inosine monophosphate and ammonia. In humans four AMPD isoforms have been described, named after the source from which they were initially purified; M (muscle), L (liver), E1 and E2 (erythrocyte), encoded by AMPD1, AMPD2 and AMPD3. Approximately 15-20% of Caucasian and African American individuals are heterozygous or homozygous for the 34C\>T variant of AMPD1. We hypothesize that healthy volunteers who have the polymorphism for AMPD1 have a less severe inflammatory response to LPS and show less (severe) organ failure. This hypothesis is based on the expected higher levels of adenosine in patients with the AMPD1 polymorphism. This hypothesis is strengthened by the fact that patients with coronary artery disease and the AMPD1 polymorphism show improved cardiovascular survival (Anderson JL et al. J Am Coll Cardiol 2000; 36: 1248-52) possibly based on higher adenosine levels by reduced AMPD activity. Furthermore the polymorphism predicts improved clinical outcome in patients with heart failure (Loh E et al. Circulation 1999) also based on a hypothetical elevation of adenosine. We hypothesize that: The C34T-polymorphism of the enzyme AMP-deaminase leads to a decreased inflammatory respons and thereby a decrease of LPS-induced tissue damage. A second hypothesis is based on the antagonism of the adenosine receptor, by caffeine; Antagonism of the adenosine receptor by caffeine leads to an increased LPS-induced inflammatory reaction and an increase in (subclinical) tissue damage?

Interventions

GENETICAMPD1 polymorphism

Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism

DRUGCaffeine infusion

Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.

DRUGplacebo

Endotoxin 2ng/kg combined with saline infusion (0.9%)

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male volunteers

Exclusion criteria

* Drug-, nicotine-, alcohol abuses * Tendency towards fainting * Relevant medical history

Design outcomes

Primary

MeasureTime frame
Hemodynamics; heart rate variability24 hrs after LPS administration
Markers of Inflammation24 hrs after LPS administration
Cytokines24 hrs after LPS administration
Sensitivity to norepinephrine24 hrs after LPS administration
Endothelial-dependent and independent vasorelaxation24 hrs after LPS administration
Mediators of Vascular reactivity24 hrs after LPS administration
Markers of endothelial damage and circulating endothelial cells24 hrs after LPS administration
Urinary excretion of markers of renal injury24 hrs after LPS administration
Neurologic testing24 hrs after LPS administration
Adenosine and related nucleotide concentrations.24 hrs after LPS administration
Additional blood samples will be drawn for measurement of: TLR-expression, Genetics; micro array analyses and determination of intercellular signalling pathways.24 hrs after LPS administration

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026